Investor Relations

Setting science in motion to create a better world

fortune 500
Investor Day

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve.

One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries.

Avantor’s differentiated and highly resilient business model positions the company to deliver results across market segments. We are progressing a long-term growth strategy based on product innovation, expansion in emerging markets and targeted M&A.

Why Avantor

Our offerings are powering innovation from scientific discovery to scale-up and commercial delivery. We further embed ourselves in our customers’ workflows through our robust service capabilities. The strengths of our model include, high recurring revenues, customized solutions, robust ecommerce platform, strong cash flow generation, enduring customer relationships and subject matter expertise.

Spotlight

vaccine

We have deep ties to the scientific and pharma industries and are supporting key breakthroughs and life-changing treatments for patients. Biopharma accounts for more than 50% of our revenue. Our portfolio of nearly 6 million different products is used in virtually every stage of the most important research, development and production work, such as monoclonal antibodies, cell and gene therapy, vaccines.

Our products are specified in more than 80% of the top 20 biologic drugs and we serve each of the world’s top 10 medical device companies.

Our strength in biopharma is underscored by the crucial role we are playing in the fight against the COVID-19 pandemic.

2021 Financial Summary1

11.3%

Organic revenue
growth

~190bps

Adj. EBITDA margin expansion

57.7%

Adj. EPS
growth

~100%

Free Cash Flow
conversion2


1. See "Reconciliations of Non-GAAP measures" in our annual report on Form 10-K and our 4Q 2021 quarterly earnings materials for a discussion of non-GAAP measures.
2. Free Cash Flow conversion is defined as Free Cash Flow / Adj. Net Income. Included in 4Q 2021 earnings materials.

Latest News

All News

Featured Video

We Set Science in Motion to Create a Better World